Show simple item record

dc.contributor.authorCastelnuovo, Barbara
dc.contributor.authorByakwaga, Hellen
dc.contributor.authorMenten, Joris
dc.contributor.authorSchaefer, Petra
dc.contributor.authorKamya, Moses
dc.contributor.authorColebunders, Robert
dc.date.accessioned2011-12-30T18:18:18Z
dc.date.available2011-12-30T18:18:18Z
dc.date.issued2008
dc.identifier.citationCastelnuovo B, Byakwaga H,Menten J. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? ,Vol 22en_US
dc.identifier.urihttp://hdl.handle.net/10570/278
dc.description.abstractBackground: A pruritic papular eruption (PPE) is a common skin manifestation observed in 12–46% of persons with HIV infection living in tropical countries. Objective: To determine whether PPE responds to HAART and whether monitoring PPE severity could be used as a clinical marker to predict virological outcome in resource limited settings where viral load testing is not available. Methods: The study enrolled 53 patients with PPE for at least 1 month before starting a first-line HAART regimen as part of a prospective study. CD4 cell count and viral load were measured at enrolment and every 3 months. A scoring system was developed to evaluate the PPE severity by asking two questions. Over the last month how itchy has your skin been? Over the last month how has itching interfered with your sleep? Results: Median CD4 cell count was 15 cells/ml and median viral load 268 663 copies/ ml. All patients initiated a regimen containing a nonnucleoside reverse transcriptase inhibitor. Mean PPE score declined from 3.9 at enrolment to 0.1 at 24 months. In 37 (86%) of the 43 patients with at least 6 months of follow-up data, the PPE disappeared and never returned. Patients with viral load >400 copies/ml at months 9 and/or 12 had significantly higher PPE scores at months 9 to 12 than the patients with <400 copies/ml. Conclusions: In most patients, PPE disappears during HAART and PPE severity scores were higher in patients whose first-line HAART failed to control plasma viral load.en_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectviral loaden_US
dc.subjectHIV/AIDSen_US
dc.subjectMonitoringen_US
dc.subjectPapular pruritic eruptionen_US
dc.subjectTreatment failureen_US
dc.titleCan response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?en_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record